Moderna, Merck race to submit personalized cancer vaccine for FDA approval by 2027

Moderna and Merck are accelerating development of a personalized cancer vaccine, targeting FDA submission by 2027. The timeline suggests a competitive race in the oncology space, with potential market implications for both companies. Details on trial results or regulatory milestones remain undisclosed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works